The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been endorsed by the ANZCTR. Before participating in a study, talk to your health care provider and refer to this information for consumers
Trial registered on ANZCTR


Registration number
Help: Registration number
ACTRN12626000728336
Ethics application status
Help: Ethics application status
Approved
Date submitted
Help: Date submitted
8/05/2026
Date registered
Help: Date registered
17/06/2026
Date last updated
Help: Date last updated
17/06/2026
Date data sharing statement initially provided
Help: Data sharing statement date
17/06/2026
Type of registration
Help: Type of registration
Prospectively registered

Titles & IDs
Public title
The impact of a new blood test for Alzheimer's disease on general practitioners' (GPs) diagnosis and management of patients.
Scientific title
Evaluating the impact of the Roche Elecsys pTau217 blood-based biomarker for Alzheimer’s disease on clinician diagnostic confidence and management in a Primary Care setting: A before and after study.
Additional trial identifiers [1] 317170 0
Nil
Universal Trial Number (UTN)
U1111-1340-1025
Trial acronym
Related trial records

Health condition
Health condition(s) studied:
Alzheimer's disease 341750 0
Condition category
Condition code
Neurological 337824 337824 0 0
Alzheimer's disease

Intervention/exposure
Study type
Interventional
Description of the intervention or exposure
Participants in this study will attend 3 visits of standard duration (10-20 minutes, per standard GP consult lengths) to their GP, one of these being in addition to standard care. They will also undergo a single blood draw between GP visits 2 and 3, in addition to standard care, to provide the sample on which the intervention will be administered. Participants will also attend a final visit of 60 minutes with a medical specialist (a neurologist, geriatrician or old age psychiatrist), per standard care.

State coordinators will monitor each participants' progression through the study visits and blood draw/testing performed under this protocol and liaise with participants' referring GPs should the activities not be completed as scheduled.

The intervention is the Roche Elecsys ptau217 plasma immunoassay for the detection of amyloid pathology. This diagnostic test will be administered at a single timepoint on blood samples of participants presenting to participating GPs for the investigation of cognitive decline.

The test will be performed by an accredited laboratory at the Florey Institute of Neuroscience and Mental Health, with results provided to GPs to inform their patient diagnoses.

Results of the assay will be made available to the participants' medical specialist and may be used by that specialist to assist diagnosis of Alzheimer's disease.
Intervention code [1] 333943 0
Diagnosis / Prognosis
Description of the comparator or control
Specialist diagnosis

A specialist clinician (neurologist, geriatrician or old age psychiatrist) will perform a standard face-to-face diagnostic assessment of each participant as would be undertaken as per standard clinical practice upon receipt of a referral from a GP.
Control group
Active

Outcomes
Primary outcome [1] 345362 0
1. Accuracy of GP diagnosis versus specialist diagnosis
Timepoint [1] 345362 0
Primary outcome will be assessed upon completion of all study procedures.
Primary outcome [2] 345464 0
2. GP feedback on acceptability and value of biomarker-assisted diagnosis in primary care. This will be assessed as a composite outcome.
Timepoint [2] 345464 0
After specialist diagnosis has been received by the GP, for a given participant
Secondary outcome [1] 461413 0
Change in confidence of GPs to use the Roche Elecsys ptau217 blood-based biomarker for AD in specific patients presenting with cognitive complaints.
Timepoint [1] 461413 0
Following the patient's third GP visit

Eligibility
Key inclusion criteria
1. Aged at least 55 years.
2. Presenting with cognitive decline symptoms – self report or identified by a clinician or other reliable informant.
3. Montreal Cognitive Assessment (MoCA) score of 18 or more, or Mini-mental Status Examination (MMSE) score of 20 or more, or Rowland Universal Dementia Assessment Scale (RUDAS) score of 18 or more, plus a Geriatric Depression Scale (GDS) score of less than 8.
4. Patient is able to give informed consent.
Minimum age
55 Years
Maximum age
No limit
Sex
Both males and females
Healthy volunteers
No
Key exclusion criteria
1. An established dementia diagnosis confirmed by a specialist.
2. Patients who do not agree to be informed of their blood biomarker result.
3. Persons at risk of suicide based on expression of intent to self-harm if found to have AD, suicide attempt in the past 5 years or current significant depression with suicidal ideation identified on the Columbia-Suicide Severity Rating Scale (C-SSRS)

Study design
Purpose of the study
Diagnosis
Allocation to intervention
Non-randomised trial
Procedure for enrolling a subject and allocating the treatment (allocation concealment procedures)
Methods used to generate the sequence in which subjects will be randomised (sequence generation)
Masking / blinding
Who is / are masked / blinded?



Intervention assignment
Other design features
Phase
Not Applicable
Type of endpoint/s
Statistical methods / analysis

Recruitment
Recruitment status
Not yet recruiting
Date of first participant enrolment
Anticipated
Actual
Date of last participant enrolment
Anticipated
Actual
Date of last data collection
Anticipated
Actual
Sample size
Target
Accrual to date
Final
Recruitment in Australia
Recruitment state(s)
NSW,SA,VIC

Funding & Sponsors
Funding source category [1] 321754 0
Commercial sector/Industry
Name [1] 321754 0
Roche Diagnostics International Limited
Country [1] 321754 0
Switzerland
Primary sponsor type
University
Name
The University of Melbourne
Address
Country
Australia
Secondary sponsor category [1] 324663 0
None
Name [1] 324663 0
Address [1] 324663 0
Country [1] 324663 0

Ethics approval
Ethics application status
Approved
Ethics committee name [1] 320300 0
Science, Technology, Engineering, Mathematics and Medicine (STEMM 3) Human Research Ethics Committee
Ethics committee address [1] 320300 0
Ethics committee country [1] 320300 0
Australia
Date submitted for ethics approval [1] 320300 0
07/01/2026
Approval date [1] 320300 0
09/01/2026
Ethics approval number [1] 320300 0

Summary
Brief summary
Trial website
Trial related presentations / publications
Public notes

Contacts
Principal investigator
Name 150010 0
Prof Christopher Rowe
Address 150010 0
Dept of Molecular Imaging and Therapy, Austin Health, Heidelberg, Vic. 3084
Country 150010 0
Australia
Phone 150010 0
+61 3 9496 5083
Fax 150010 0
Email 150010 0
Contact person for public queries
Name 150011 0
Dr Jo Robertson
Address 150011 0
The Florey Institute of Neuroscience and Mental Health, 155 Oak Street, Parkville Vic 3052
Country 150011 0
Australia
Phone 150011 0
+61 408508121
Fax 150011 0
Email 150011 0
Contact person for scientific queries
Name 150012 0
Dr Jo Robertson
Address 150012 0
The Florey Institute of Neuroscience and Mental Health, 155 Oak Street, Parkville Vic 3052
Country 150012 0
Australia
Phone 150012 0
+61 408508121
Fax 150012 0
Email 150012 0

Data sharing statement
Will the study consider sharing individual participant data?
No


What supporting documents are/will be available?

No Supporting Document Provided


Results publications and other study-related documents

Documents added manually
No documents have been uploaded by study researchers.

Documents added automatically
No additional documents have been identified.